Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
Garg, Mamta
Garg, Mamta
Abstract
Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple-class refractory disease. We report the use of belantamab mafodotin, a BCMA-directed drug-antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty-one patients were reviewed, with a median of three prior lines of therapy. The median follow-up was 12 months (95% CI 4-19), and a median of five doses were delivered. The best haematological overall response rate was 71%, and the complete/very good partial response was 58%. Sixty-eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis.
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2024-01-03
Type
Article
Subject
Collections
Citation
Khwaja, J., Bomsztyk, J., Atta, M., Bygrave, C., Forbes, A., Durairaj, S., Fernandes, S., Taylor, J., Paterson, P., Brearton, G., Crawley, C., Sheehy, O., Brown, R., Soutar, R., Garg, M., Rydzewski, A., Jamroziak, K., Mahmood, S., & Wechalekar, A. D. (2024). Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis. British journal of haematology, 10.1111/bjh.19286. Advance online publication. https://doi.org/10.1111/bjh.19286